The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Novo Nordisk is the global GLP-1 volume market ... and it will be effective in the 1st of January 2027. And just for background, the rough U.S. channel mix across our portfolio is about 50% ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

A patient advocacy group has started a campaign to stop Novo Nordisk from following through ... basal insulins – used to provide a background dose of insulin – are not always suitable for ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Background Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart ...

Shares of Novo Nordisk surged 10% after promising trial ... He is the author of two books on technical analysis and has a background in both futures and stock markets.

Ancient DNA is telling us more and more about humans and environments long past. Could it also help rescue the future?

The weight-loss drug boom has transformed Eli Lilly (LLY), the maker of Zepbound, into the largest healthcare company in the ...